All In Biotech

Drug Trial Radar · NCT07066657

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

572

Planned (sponsor's estimate)

Start

Jul 25, 2025

Primary completion

Mar 2028

Study completion Dec 2030

Sponsor

Lead sponsor
ArriVent BioPharma, Inc.Industry
Sponsor type
Industry
Collaborators
Lepu Biopharma Co., Ltd.
First posted
Jul 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced or Metastatic Solid Tumors
  • Colorectal Cancer
  • Gastric Cancer
  • Pancreatic Cancer

Interventions

  • MRG007Drug

    MRG007 will be administrated as specified in the protocol.

  • MRG007 and BevacizumabDrug

    MRG007 will be administered as specified in the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting Toxicity (DLT) - Phase IaTime frame: Baseline to Day 21 of the first treatment cycle
  2. Serious Adverse Events (SAEs)Time frame: Baseline to 30 days after the last dose of study treatment
  3. Treatment-Emergent Adverse Event (TEAE)Time frame: Baseline to 30 days after the last dose of study treatment
  4. Treatment-Related Adverse EventTime frame: Baseline to 30 days after the last dose of study treatment
  5. Objective Response Rate (ORR) as assessed by investigator - Phase IbTime frame: Baseline to study completion (up to 24 months)

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • ULCA

    Los Angeles, California · Recruiting

  • UCSF

    San Francisco, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • Sarah Cannon Research Institute

    Denver, Colorado · Recruiting

  • Sarah Cannon Research Institute

    Sarasota, Florida · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Dallas

    Irving, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Gobroad Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing Daping Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Zhejiang, Hangzhou, China · Recruiting

  • Harbin Medical University Cancer Hospital

    Heilongjiang, Harbin, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Cancer Hospital of Shandong First Medical University

    Shandong, Jinan, China · Recruiting

  • Renji Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

  • Zhongshan Hospital Fudan University

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.